MARKET

ATRA

ATRA

Atara Biotherapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

15.03
-0.96
-6.00%
Closed 16:41 01/17 EST
OPEN
16.08
PREV CLOSE
15.99
HIGH
16.15
LOW
15.03
VOLUME
645.62K
TURNOVER
--
52 WEEK HIGH
41.97
52 WEEK LOW
10.38
MARKET CAP
813.88M
P/E (TTM)
-2.4665
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ATRA and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ATRA News

  • Atara Biotherapeutics to Present 2020 Key Milestones and Progress in Bringing Off-The-Shelf, Allogeneic T-Cell Immunotherapies to Patients in Need at the 38th Annual J.P. Morgan Healthcare Conference
  • Benzinga.01/12 19:51
  • Atara Biotherapeutics to Present 2020 Key Milestones and Progress in Bringing Off-The-Shelf, Allogeneic T-Cell Immunotherapies to Patients in Need at the 38th Annual J.P. Morgan Healthcare Conference
  • GlobeNewswire.01/12 19:00
  • Trade Deal Optimism Fuels Santa Rally: ETFs & Stocks to Bet On
  • Zacks.12/24/2019 15:10
  • Fate Therapeutics: Using Cell Programming To Produce Better Cell Therapies
  • Seeking Alpha - Article.12/20/2019 21:27

More

Industry

Biotechnology & Medical Research
-0.16%
Pharmaceuticals & Medical Research
+0.06%

Hot Stocks

Name
Price
%Change

About ATRA

Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells. T-cells are a type of white blood cell. The Company's product candidate, ATA129, is a third-party derived Epstein-Barr virus CTL for the treatment of Epstein-Barr virus (EBV). ATA188 is in development for the treatment of multiple sclerosis. ATA520, which is a third-party donor derived WT1-CTL, targets cancers expressing the antigen Wilms Tumor 1 (WT1). ATA520 is in Phase I clinical trials. The Company's T-cell product candidate, ATA230, which is a third-party derived cytomegalovirus-CTL (CMV-CTL), is in Phase II clinical trials for refractory CMV.
More

Webull offers Atara Biotherapeutics Inc (ATRA) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.